NASDAQ:ESLA Estrella Immunopharma Q4 2025 Earnings Report $0.53 +0.00 (+0.57%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.52 -0.01 (-2.46%) As of 09/18/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Estrella Immunopharma EPS ResultsActual EPS-$0.13Consensus EPS -$0.19Beat/MissBeat by +$0.06One Year Ago EPSN/AEstrella Immunopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEstrella Immunopharma Announcement DetailsQuarterQ4 2025Date11/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEstrella Immunopharma's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Estrella Immunopharma Earnings HeadlinesESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 TrialAugust 26, 2026 | finance.yahoo.comEstrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaAugust 11, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJuly 29, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaJuly 24, 2026 | finance.yahoo.comEstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's LymphomaJuly 24, 2026 | businesswire.comSee More Estrella Immunopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Estrella Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Estrella Immunopharma and other key companies, straight to your email. Email Address About Estrella ImmunopharmaEstrella Immunopharma (NASDAQ:ESLA) is a clinical-stage biopharmaceutical company focused on developing T-cell immunotherapies for cancer and potentially other serious diseases. Its research centers on genetically engineered T cells designed to recognize and attack disease-associated targets. The company’s primary development focus is its CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy programs. These therapies are intended to treat certain B-cell malignancies by directing a patient’s immune cells against CD19, a protein commonly found on malignant B cells. Estrella is working to advance its candidates through preclinical and clinical development while seeking to improve the effectiveness, durability and safety of CAR-T treatment. Publicly available information provides limited detail about the company’s commercial operations, geographic reach and leadership beyond its focus on developing immunotherapies. Estrella does not appear to have an established commercial product portfolio, and its programs remain centered on research and development.View Estrella Immunopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
